HSBC Research maintained a Buy rating on WUXI APPTEC due to strong year-on-year growth in revenue and adjusted net profit, particularly in the small molecule CDMO business, which exceeded expectations. The company also provided positive guidance for future growth, prompting the broker to raise its profit forecasts and target prices for both H shares and A shares.
